These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 23921784

  • 21. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW, Oh JS, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY.
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [Abstract] [Full Text] [Related]

  • 22. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P, Janvary ZL, Coucke P, Jodogne S, Bernard C, Hatt M, Visvikis D, Jansen N, Duysinx B, Hustinx R.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [Abstract] [Full Text] [Related]

  • 23. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.
    Liu J, Dong M, Sun X, Li W, Xing L, Yu J.
    PLoS One; 2016 Jul; 11(1):e0146195. PubMed ID: 26727114
    [Abstract] [Full Text] [Related]

  • 24. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [Abstract] [Full Text] [Related]

  • 25. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C, Liao C, Penney BC, Appelbaum DE, Simon CA, Pu Y.
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [Abstract] [Full Text] [Related]

  • 26. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [Abstract] [Full Text] [Related]

  • 27. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
    Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, Wong R, Fury M, Schöder H.
    J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
    [Abstract] [Full Text] [Related]

  • 28. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?
    Akkas BE, Demirel BB, Dizman A, Vural GU.
    Ann Nucl Med; 2013 Oct; 27(8):756-63. PubMed ID: 23793926
    [Abstract] [Full Text] [Related]

  • 29. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
    Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, Kang SB, Kim JW.
    Ann Surg Oncol; 2012 Jun; 19(6):1966-72. PubMed ID: 22124757
    [Abstract] [Full Text] [Related]

  • 30. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, Downey R, Rosenzweig KE, Weber WA, Rimner A.
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [Abstract] [Full Text] [Related]

  • 32. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1033-9. PubMed ID: 20472359
    [Abstract] [Full Text] [Related]

  • 33. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY, Guo Z, Sun J, Yang WP, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2018 Jul 23; 40(7):528-533. PubMed ID: 30060362
    [Abstract] [Full Text] [Related]

  • 34. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
    Sun Y, Lu P, Yu L.
    Acad Radiol; 2016 May 23; 23(5):605-10. PubMed ID: 26853968
    [Abstract] [Full Text] [Related]

  • 35. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, Herschtal A, Binns D, Kron T, Schneider M, MacManus M.
    J Nucl Med; 2014 Jul 23; 55(7):1069-74. PubMed ID: 24833494
    [Abstract] [Full Text] [Related]

  • 36. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ, Wu N, Zheng R, Liu Y, Zhang WJ, Liang Y, Zhang H, Li XM.
    Zhonghua Zhong Liu Za Zhi; 2013 Oct 23; 35(10):754-7. PubMed ID: 24378097
    [Abstract] [Full Text] [Related]

  • 37. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A, Fledelius J, Sorensen BS, Meldgaard P.
    Lung Cancer; 2016 Apr 23; 94():81-7. PubMed ID: 26973211
    [Abstract] [Full Text] [Related]

  • 38. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
    Ogawa S, Itabashi M, Kondo C, Momose M, Sakai S, Kameoka S.
    Anticancer Res; 2015 Jun 23; 35(6):3495-500. PubMed ID: 26026116
    [Abstract] [Full Text] [Related]

  • 39. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP.
    Ther Adv Respir Dis; 2014 Feb 23; 8(1):3-12. PubMed ID: 24334338
    [Abstract] [Full Text] [Related]

  • 40. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB, Siegel BA, Machtay M, Alavi A.
    Eur J Nucl Med Mol Imaging; 2017 Nov 23; 44(12):1969-1983. PubMed ID: 28689281
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.